Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CCNA2 | P20248 | 5/20 | 0.44 |
| ▸ | CDK2 | P24941 | 5/20 | 0.44 |
| ▸ | CCNA1 | P78396 | 5/20 | 0.44 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.44 |
| ▸ | CDK9 | P50750 | 1/20 | 0.44 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.44 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.44 |
| ▸ | MAPK8 | P45983 | 6/20 | 0.39 |
| ▸ | MAPK10 | P53779 | 5/20 | 0.39 |
| ▸ | MAPK9 | P45984 | 4/20 | 0.39 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.38 |
| ▸ | CDK1 | P06493 | 4/20 | 0.36 |
| ▸ | CDK4 | P11802 | 4/20 | 0.36 |
| ▸ | CCNB1 | P14635 | 4/20 | 0.36 |
| ▸ | CCND1 | P24385 | 4/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2963770 | 0.82 | LMNA (0.47) | LMNACCNA2CDK2CCNA1CCNT1 | |
| SCHEMBL6132086 | 0.81 | TGFBR1 (0.50) | LMNACCNA2CDK2CCNA1CCNT1 | |
| SCHEMBL6069697 | 0.79 | LMNA (0.40) | LMNACCNA2CDK2CCNA1CCNT1 | |
| SCHEMBL6070097 | 0.74 | TGFBR1 (0.60) | CDK2CDK1KDM4EL3MBTL1MAPK1 | |
| SCHEMBL18438753 | 0.74 | CCNA2 (0.41) | LMNACCNA2CDK2CCNA1CCNT1 | |
| SCHEMBL24251294 | 0.73 | LMNA (0.47) | LMNACCNA2CDK2CCNA1CCNT1 | |
| SCHEMBL30931966 | 0.73 | LMNA (0.47) | LMNACCNA2CDK2CCNA1CCNT1 | |
| SCHEMBL8233834 | 0.73 | CCNA2 (0.50) | LMNACCNA2CDK2CCNA1CCNT1 | |
| SCHEMBL6070786 | 0.71 | LMNA (0.44) | LMNACCNA2CDK2CCNA1CCNT1 | |
| SCHEMBL16877199 | 0.71 | LMNA (0.42) | LMNACCNA2CDK2CCNA1CCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772246-B2 | Pyrazole compounds as RAF inhibitors | PFIZER INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-7772246-B2 | Pyrazole compounds as RAF inhibitors | PFIZER INC. (US) | 2010-08-10 | — | — | US | disclosed |
| US-7772246-B2 | Pyrazole compounds as RAF inhibitors | PFIZER INC. (US) | 2010-08-10 | — | — | US | disclosed |
| EP-2183243-A2 | PYRAZOLE COMPOUNDS AND THEIR USE AS RAF INHIBITORS | Pfizer Inc. (US) | 2010-05-12 | — | — | EP | disclosed |
| US-20090221608-A1 | PYRAZOLE COMPOUNDS | PFIZER INC. | 2009-09-03 | — | — | US | disclosed |
| US-20090221608-A1 | PYRAZOLE COMPOUNDS | PFIZER INC. | 2009-09-03 | — | — | US | disclosed |
| US-20090221608-A1 | PYRAZOLE COMPOUNDS | PFIZER INC. | 2009-09-03 | — | — | US | disclosed |
| WO-2009016460-A2 | PYRAZOLE COMPOUNDS AND THEIR USE AS RAF INHIBITORS | PFIZER INC. (US) | 2009-02-05 | — | — | WO | disclosed |
| WO-2009016460-A2 | PYRAZOLE COMPOUNDS AND THEIR USE AS RAF INHIBITORS | PFIZER INC. (US) | 2009-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221608-A1 | PYRAZOLE COMPOUNDS | BRAF, RAF1, NRAS | LMNA 4718/4885CCNA2 1821/4885CDK2 182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.